151 related articles for article (PubMed ID: 14742187)
1. Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations.
Turtinen LW; Prall DN; Bremer LA; Nauss RE; Hartsel SC
Antimicrob Agents Chemother; 2004 Feb; 48(2):396-403. PubMed ID: 14742187
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B.
Simitsopoulou M; Roilides E; Dotis J; Dalakiouridou M; Dudkova F; Andreadou E; Walsh TJ
Antimicrob Agents Chemother; 2005 Apr; 49(4):1397-403. PubMed ID: 15793118
[TBL] [Abstract][Full Text] [Related]
3. Distinct cytokine release profiles from human endothelial and THP-1 macrophage-like cells exposed to different amphotericin B formulations.
Turtinen LW; Bremer LA; Prall DN; Schwartzhoff J; Hartsel SC
Immunopharmacol Immunotoxicol; 2005; 27(1):85-93. PubMed ID: 15803862
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis.
Clemons KV; Stevens DA
Antimicrob Agents Chemother; 1998 Apr; 42(4):899-902. PubMed ID: 9559804
[TBL] [Abstract][Full Text] [Related]
5. Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus.
Simitsopoulou M; Roilides E; Georgiadou E; Paliogianni F; Walsh TJ
Med Mycol; 2011 Feb; 49(2):176-85. PubMed ID: 20807031
[TBL] [Abstract][Full Text] [Related]
6. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
7. Microarray analysis of amphotericin B-treated THP-1 monocytic cells identifies unique gene expression profiles among lipid and non-lipid drug formulations.
Turtinen LW; Croswell A; Obr A
J Chemother; 2008 Jun; 20(3):327-35. PubMed ID: 18606588
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
9. Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1.
Rogers PD; Barker KS; Herring V; Jacob M
J Antimicrob Chemother; 2003 Feb; 51(2):405-8. PubMed ID: 12562711
[TBL] [Abstract][Full Text] [Related]
10. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
11. Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan.
Falk R; Hacham M; Nyska A; Foley JF; Domb AJ; Polacheck I
J Antimicrob Chemother; 2005 May; 55(5):713-20. PubMed ID: 15814605
[TBL] [Abstract][Full Text] [Related]
12. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.
Sidhu R; Lash DB; Heidari A; Natarajan P; Johnson RH
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686150
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga M; Alonso R; del Valle O; Rodriguez V; Arévalo MP; Salgado J; Martin-Mazuelos E; Bornay-Llinares FJ; del Palacio A; Cuétara M; Gasser I; Hernández-Molina JM; Pemán J
Chemotherapy; 2000; 46(4):235-44. PubMed ID: 10859429
[TBL] [Abstract][Full Text] [Related]
15. Cytokines in mice treated with amphotericin B-intralipid.
Shadkchan Y; Keisari Y; Segal E
Med Mycol; 2004 Apr; 42(2):123-8. PubMed ID: 15124865
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
17. Antifungal antibiotics modulate the pro-inflammatory cytokine production and phagocytic activity of human monocytes in an in vitro sepsis model.
Muenster S; Bode C; Diedrich B; Jahnert S; Weisheit C; Steinhagen F; Frede S; Hoeft A; Meyer R; Boehm O; Knuefermann P; Baumgarten G
Life Sci; 2015 Nov; 141():128-36. PubMed ID: 26382596
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
19. Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations.
Dinh T; Zia Q; Zubair S; Stapleton P; Singh R; Owais M; Somavarapu S
Nanomedicine; 2017 Jul; 13(5):1773-1783. PubMed ID: 28216150
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary extraction and accumulation of lipid formulations of amphotericin B.
Matot I; Pizov R
Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
